Treace Medical Concepts Inc. is a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus. Treace Medical Concepts Inc. is based in PONTE VEDRA, Fla.
| Revenue (Most Recent Fiscal Year) | $209.36M |
| Net Income (Most Recent Fiscal Year) | $-55.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.19 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -23.01% |
| Net Margin (Trailing 12 Months) | -23.01% |
| Return on Equity (Trailing 12 Months) | -46.76% |
| Return on Assets (Trailing 12 Months) | -23.35% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.55 |
| Inventory Turnover (Trailing 12 Months) | 1.04 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.55 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 63.17M |
| Free Float | 45.66M |
| Market Capitalization | $467.48M |
| Average Volume (Last 20 Days) | 0.42M |
| Beta (Past 60 Months) | 0.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 27.72% |
| Percentage Held By Institutions (Latest 13F Reports) | 84.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |